No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NRXP240621C500
- 0.35
- 0.000.00%
15min DelayClose Mar 11 11:16 ET
0.00High0.00Low
0.00Open0.35Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover2376.59%IV-70.69%PremiumJun 21, 2024Expiry Date2.40Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9784Delta0.0141Gamma1.18Leverage Ratio-0.0500Theta0.0000Rho1.16Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
News
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced that...
Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) Appoints Neuroscience, Information Technology and Medical Technology Veteran to Its Board of Directors
NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company's Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of car
Express News | NRX Pharmaceuticals Inc: Expect to Complete Stability Portion of Our New Drug Application for Ketamine by September
Express News | NRX Pharmaceuticals: Reached 9-Month Stability Point With Its Ketamine Formulation (NRX-100), Initiated 3 Manufacturing Lots for Future Drug Release
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the ...
Comments
$NRX Pharmaceuticals (NRXP.US)$ Here is why OCGN will skyrocket 400% to 800% over the next 9 to 12 months.
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...
What is OCU400's market potential? If we take Ocugen's estimates seriously, it is mouthwatering. The biotech projects that OCU400 could earn approval in 2026. Ocugen thinks the therapy could generate between $30 billion and $47 billion in total revenue in the five years after approval. The company's market cap is about $488 million as of this writing. So by any standar...
12
Encouraged by these results, NRx Pharmaceuticals plans to seek accelerated FDA approval for NRX-101 for patients with bipolar depression at risk of akathisia.
Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidon...
Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidon...
Read more